Captisol-enabled melphalan: Phase IIa started

CyDex began an open-label, active-controlled, crossover Phase IIa trial to compare 100 mg/m 2 IV Captisol-enabled melphalan vs. IV Alkeran melphalan in 24 patients. The product has Orphan Drug design...